Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"UK industry needs 0.25% cut in interest rates":

This article was originally published in Clinica

Executive Summary

UK industry needs a 0.25% cut in interest rates, says the Trades Union Congress (TUC), the manufacturing and services sectors' main representative body, in order to encourage investment. Its calls come despite relatively positive GDP data that puts overall output growth at around 1.9%. Although this is in line with treasury predictions, temporarily easing the pressure on increased investment, manufacturing continues to suffer, says the TUC. "Manufacturing output is contracting by around 6% annually," Ian Brinkley, TUC senior economist, told Clinica. Although the overall economy is buoyed by 3.6% growth in the services industry, it remains below the long-term average for the UK. The Association of British Health-Care Industries (ABHI) has echoed these concerns, particularly in view of the strength of sterling (see Clinica No 991, p 7). The TUC is due to publish its budget submission on February 11 and discuss it at its pre-budget conference on February 28.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel